Drugs / HCW9302
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07049328 | Aug 2025 → Jul 2026 overdue | alopecia areata | HCW Biologics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-16 | HCW Biologics | Results HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata hcwbiologics.com ↗ |
| 2025-02-03 | HCW Biologics | Regulatory HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial hcwbiologics.com ↗
today announced that it has received clearance of its Investigational New Drug Application (“IND”) from the U.S. Food and Drug Administration (“FDA”) to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302 |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCW9302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07049328 ↗ |
| Modality | Protein / enzyme biologic | “HCW9302, an IL-2 fusion protein” NCT07049328 ↗ |
| Route | Subcutaneous | “HCW9302 will be administered subcutaneously” NCT07049328 ↗ |